Pyxis Oncology, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-08. Between them they name 2 people, with 2 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Thomas Civik, Chief Executive Officer
On September 4, 2026, the Board of Directors (the "Board") of Pyxis Oncology, Inc. (the "Company") appointed Thomas Civik, the Company's Interim Chief Executive Officer, to serve as the Company's permanent Chief Executive Officer, effective immediately (the "Appointment").
Appointed: Thomas Civik, Chairman of the Board, effective 2026-09-04
Board Leadership and Committee Changes In connection with the Appointment, the Board determined to combine the roles of Chairman of the Board and Chief Executive Officer and appointed Mr. Civik as Chairman of the Board, effective September 4, 2026.
Departing: Santhosh Palani, effective 2026-09-04
Board Member Resignation and Related Matters On September 3, 2026, Dr. Santhosh Palani, Ph.D., CFA, notified the Company of his resignation as a member of the Company's Board and all committees on which he served, effective as of September 4, 2026.
Reported
Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.
Find people with the same kind of experience as the Chief Executive Officer at Pyxis Oncology, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Pyxis Oncology, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Pyxis Oncology, Inc. is in the news or changes leadership.
Get an alert when Pyxis Oncology, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Pyxis Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.